Summary
4.26 -0.08(-1.90%)07/02/2024
Geron Corp. (GERN)
Geron Corp. (GERN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.90 | -5.67 | 13.22 | 36.22 | 102.10 | 36.01 | 206.74 | -41.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.26 | |
| Open | 4.34 | |
| High | 4.37 | |
| Low | 4.24 | |
| Volume | 799,651 | |
| Change | -0.08 | |
| Change % | -1.90 | |
| Avg Volume (20 Days) | 9,163,900 | |
| Volume/Avg Volume (20 Days) Ratio | 0.09 | |
| 52 Week Range | 1.64 - 5.34 | |
| Price vs 52 Week High | -20.27% | |
| Price vs 52 Week Low | 159.60% | |
| Range | 2.00 | |
| Gap Up/Down | -0.24 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,574 | |
| EBIDTA | -209,532,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -2.3800 | |
| WallStreet Target Price | 6.07 | |
| Book Value | 0.5830 | |
| Earnings Per Share | -0.3400 | |
| EPS Estimate Current Quarter | -0.1000 | |
| EPS Estimate Next Quarter | -0.1000 | |
| EPS Estimate Current Year | -0.3500 | |
| EPS Estimate Next Year | -0.1700 | |
| Diluted EPS (TTM) | -0.3400 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -184.6513 | |
| Return on asset (TTM) | -0.2894 | |
| Return on equity (TTM) | -0.6004 | |
| Revenue TTM | 520,000 | |
| Revenue per share TTM | 0.0010 | |
| Quarterly Revenue Growth (YOY) | 13.4760 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -93,668,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.6448 | |
| Revenue Enterprise Value | 7,998.6336 | |
| EBITDA Enterprise Value | -10.8459 | |
| Shares | ||
| Shares Outstanding | 593,132,992 | |
| Shares Float | 546,156,443 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 0.09 | |
| Institutions (%) | 68.14 | |
06/20 16:30 EST - businesswire.com
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on June 19, 2024, at an exercise price of $4.49 per share, which is equal to the closing price of Geron common stock o.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on June 19, 2024, at an exercise price of $4.49 per share, which is equal to the closing price of Geron common stock o.
06/11 10:00 EST - investorplace.com
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
06/10 13:01 EST - zacks.com
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
06/08 06:37 EST - fool.com
Is Geron Stock a Buy Following Its First New Drug Approval?
The U.S. Food and Drug Administration approved Geron's lead candidate on June 6, under the brand name Rytelo. Peak Rytelo sales could surpass $1 billion annually.
Is Geron Stock a Buy Following Its First New Drug Approval?
The U.S. Food and Drug Administration approved Geron's lead candidate on June 6, under the brand name Rytelo. Peak Rytelo sales could surpass $1 billion annually.
06/07 16:10 EST - investopedia.com
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
06/07 12:57 EST - marketbeat.com
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for complex diseases.
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for complex diseases.
06/07 11:02 EST - investorplace.com
Why Is Geron (GERN) Stock Up 18% Today?
Geron (NASDAQ: GERN ) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company's “adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent ( TD ) anemia.
Why Is Geron (GERN) Stock Up 18% Today?
Geron (NASDAQ: GERN ) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company's “adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent ( TD ) anemia.
06/07 06:04 EST - reuters.com
Geron shares surge after U.S. FDA approves blood disorder drug
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients with a group of blood cancers.
Geron shares surge after U.S. FDA approves blood disorder drug
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients with a group of blood cancers.
06/06 21:58 EST - businesswire.com
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not respon.
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not respon.
05/23 17:49 EST - seekingalpha.com
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness of Imetelstat in inhibiting telomerase and treating diseases. The FDA Oncologic Drugs Advisory Committee voted in favor of Imetelstat (12 to 2) for patients with MDS.
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness of Imetelstat in inhibiting telomerase and treating diseases. The FDA Oncologic Drugs Advisory Committee voted in favor of Imetelstat (12 to 2) for patients with MDS.
05/02 09:21 EST - zacks.com
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.
05/02 07:00 EST - businesswire.com
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024. “Since the FDA ODAC's 12 to 2 vote in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS in Mar.
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024. “Since the FDA ODAC's 12 to 2 vote in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS in Mar.
05/02 06:46 EST - investorplace.com
The Top 3 Penny Stocks to Buy in April 2024
Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heightened volatility, translating into significant short-term gains for those adept at timing the market.
The Top 3 Penny Stocks to Buy in April 2024
Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heightened volatility, translating into significant short-term gains for those adept at timing the market.
05/01 16:23 EST - seekingalpha.com
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetelstat 12 to 2 for patients with low-risk myelodysplastic syndrome. The European Commission has already accepted the MAA for review of imetelstat for low-risk myelodysplastic syndrome; European approval is possible in 2025.
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetelstat 12 to 2 for patients with low-risk myelodysplastic syndrome. The European Commission has already accepted the MAA for review of imetelstat for low-risk myelodysplastic syndrome; European approval is possible in 2025.
04/28 04:39 EST - seekingalpha.com
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.
04/25 16:30 EST - businesswire.com
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A l.
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A l.
04/03 16:30 EST - businesswire.com
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23rd Annual Needham Virtual Healthcare Conference Wednesday, April 10th at 10:15 a.m. ET (Fireside Chat) Stifel's 2024 Virtual Targeted Oncology Days Wednesday, April 17th at 11:30 a.m. ET (Corporate Presentation) A.
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23rd Annual Needham Virtual Healthcare Conference Wednesday, April 10th at 10:15 a.m. ET (Fireside Chat) Stifel's 2024 Virtual Targeted Oncology Days Wednesday, April 17th at 11:30 a.m. ET (Corporate Presentation) A.
03/20 06:10 EST - marketbeat.com
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.